Lunit will present its findings on artificial intelligence (AI)-based, pathology tissue analysis at the American Society of Clinical Oncology (ASCO) annual meeting, which will be held June 4-8.
The presentations feature the company's Lunit Scope, an AI software application that analyzes tissue slide images. One finding showed that Lunit Scope IO can be used as a biomarker for the treatment of multiple cancer types. The software analyzes tumor-infiltrating lymphocytes in tissue slides for cancer patients, assigning a score to each criterion.
Company leaders said that in validation with real-world data, the results showed the higher the score, the better the response to immune checkpoint inhibitor treatment, a subtype of immunotherapy.
Lunit also announced that one of its abstracts about assessment of breast cancer risk has been selected for the ASCO 2021 poster discussion session.
Lunit will present findings on its AI-based tissue analysis software at ASCO 2021. Image courtesy of Lunit.
